BACKGROUND: Evidence-based guidelines recommend routine surveillance, including office visits and testing, to detect new and recurrent disease among survivors of breast and colorectal cancer. The extent to which surveillance practice is consistent with guideline recommendations or may vary by age is not known. METHODS: Cohorts of adult patients diagnosed with breast (n = 6205) and colorectal (n = 2297) cancer between 2000 and 2008 and treated with curative intent in 4 geographically diverse managed care environments were identified via tumor registries. Kaplan-Meier estimates were used to describe time to initial and subsequent receipt of surveillance services. Cox proportional hazards models evaluated the relation between patient characteristics and receipt of metastatic screening. RESULTS: Within 18 months of treatment, 87.2% of breast cancer survivors received recommended mammograms, with significantly higher rates noted for patients aged 50 years to 65 years. Among survivors of colorectal cancer, only 55.0% received recommended colon examinations, with significantly lower rates for those aged ≥ 75 years. The majority of breast (64.7%) and colorectal (73.3%) cancer survivors received nonrecommended metastatic disease testing. In patients with breast cancer, factors associated with metastatic disease testing include white race (hazards ratio [HR], 1.13), comorbidities (HR, 1.17), and younger age (HR, 1.13; 1.15; 1.13 for age groups: <50, 50-64, and 65-74 respectively). In those with colorectal cancer, these factors included younger age (HR, 1.31; 1.25 for age groups: <50 and 50-64 respectively) and comorbidities (HR, 1.10). CONCLUSIONS: Among an insured population, wide variation regarding the use of surveillance care was found by age and relative to guideline recommendations. Breast cancer survivors were found to have high rates of both guideline-recommended recurrence testing and non-guideline-recommended metastatic testing. Only approximately 50% of colorectal cancer survivors received recommended tests but greater than 67% received metastatic testing.
BACKGROUND: Evidence-based guidelines recommend routine surveillance, including office visits and testing, to detect new and recurrent disease among survivors of breast and colorectal cancer. The extent to which surveillance practice is consistent with guideline recommendations or may vary by age is not known. METHODS: Cohorts of adult patients diagnosed with breast (n = 6205) and colorectal (n = 2297) cancer between 2000 and 2008 and treated with curative intent in 4 geographically diverse managed care environments were identified via tumor registries. Kaplan-Meier estimates were used to describe time to initial and subsequent receipt of surveillance services. Cox proportional hazards models evaluated the relation between patient characteristics and receipt of metastatic screening. RESULTS: Within 18 months of treatment, 87.2% of breast cancer survivors received recommended mammograms, with significantly higher rates noted for patients aged 50 years to 65 years. Among survivors of colorectal cancer, only 55.0% received recommended colon examinations, with significantly lower rates for those aged ≥ 75 years. The majority of breast (64.7%) and colorectal (73.3%) cancer survivors received nonrecommended metastatic disease testing. In patients with breast cancer, factors associated with metastatic disease testing include white race (hazards ratio [HR], 1.13), comorbidities (HR, 1.17), and younger age (HR, 1.13; 1.15; 1.13 for age groups: <50, 50-64, and 65-74 respectively). In those with colorectal cancer, these factors included younger age (HR, 1.31; 1.25 for age groups: <50 and 50-64 respectively) and comorbidities (HR, 1.10). CONCLUSIONS: Among an insured population, wide variation regarding the use of surveillance care was found by age and relative to guideline recommendations. Breast cancer survivors were found to have high rates of both guideline-recommended recurrence testing and non-guideline-recommended metastatic testing. Only approximately 50% of colorectal cancer survivors received recommended tests but greater than 67% received metastatic testing.
Authors: C E Desch; A B Benson; T J Smith; P J Flynn; C Krause; C L Loprinzi; B D Minsky; N J Petrelli; D G Pfister; M R Somerfield Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: Melinda Kantsiper; Erin L McDonald; Gail Geller; Lillie Shockney; Claire Snyder; Antonio C Wolff Journal: J Gen Intern Med Date: 2009-11 Impact factor: 5.128
Authors: Berta M Geller; Karla Kerlikowske; Patricia A Carney; Linn A Abraham; Bonnie C Yankaskas; Stephen H Taplin; Rachel Ballard-Barbash; Mark B Dignan; Robert Rosenberg; Nicole Urban; William E Barlow Journal: Breast Cancer Res Treat Date: 2003-09 Impact factor: 4.872
Authors: Sidney Winawer; Robert Fletcher; Douglas Rex; John Bond; Randall Burt; Joseph Ferrucci; Theodore Ganiats; Theodore Levin; Steven Woolf; David Johnson; Lynne Kirk; Scott Litin; Clifford Simmang Journal: Gastroenterology Date: 2003-02 Impact factor: 22.682
Authors: Julia R Berian; Amanda Cuddy; Amanda B Francescatti; Linda O'Dwyer; Y Nancy You; Robert J Volk; George J Chang Journal: J Cancer Surviv Date: 2017-06-22 Impact factor: 4.442
Authors: Shrujal S Baxi; Minal Kale; Salomeh Keyhani; Benjamin R Roman; Annie Yang; Antonio P Derosa; Deborah Korenstein Journal: Med Care Date: 2017-07 Impact factor: 2.983
Authors: Jennifer Elston Lafata; Ramzi G Salloum; Paul A Fishman; Debra Pearson Ritzwoller; Maureen C O'Keeffe-Rosetti; Mark C Hornbrook Journal: J Cancer Surviv Date: 2014-09-25 Impact factor: 4.442
Authors: Maria Pisu; Cheryl L Holt; Aquila Brown-Galvan; Temeika Fairley; Judith Lee Smith; Arica White; Ingrid J Hall; Robert A Oster; Michelle Y Martin Journal: J Oncol Pract Date: 2014-01-02 Impact factor: 3.840
Authors: Larissa Nekhlyudov; Sarah M Greene; Jessica Chubak; Borsika Rabin; Leah Tuzzio; Sharon Rolnick; Terry S Field Journal: J Cancer Surviv Date: 2012-12-14 Impact factor: 4.442
Authors: Benjamin R Roman; Shivangi Lohia; Nandita Mitra; Marilene B Wang; Anna M Pou; F Christopher Holsinger; David Myssiorek; David Goldenberg; David A Asch; Judy A Shea Journal: Head Neck Date: 2020-01-10 Impact factor: 3.147
Authors: Betsy C Risendal; Rebecca L Sedjo; Anna R Giuliano; Susan Vadaparampil; Paul B Jacobsen; Kristin Kilbourn; Anna Barón; Tim Byers Journal: J Cancer Surviv Date: 2015-06-13 Impact factor: 4.442
Authors: Melissa Y Carpentier; Sally W Vernon; L Kay Bartholomew; Caitlin C Murphy; Shirley M Bluethmann Journal: J Cancer Surviv Date: 2013-05-16 Impact factor: 4.442